The surge in urinary tract infection testing demand is mainly propelled by the increasing worldwide instances of UTIs, the rise in hospital-acquired UTIs, and the preference for home and self-testing kits for early UTI detection, among other factors. Additionally, the market for UTI testing is expected to expand due to numerous ongoing research endeavors, collaborations among healthcare providers, researchers, and industry stakeholders, as well as strategic partnerships. These factors are poised to fuel the growth of the UTI testing market from 2024 to 2030.
LAS VEGAS , May 29, 2024 /PRNewswire/ -- DelveInsight's Urinary Tract Infection Testing Market Insights report provides the current and forecast market analysis, individual leading urinary tract infection testing companies' market shares, challenges, urinary tract infection testing market drivers, barriers, trends, and key market urinary tract infection testing companies in the market. Key Takeaways from the Urinary Tract Infection Testing Market Report As per DelveInsight estimates, North America is anticipated to dominate the global urinary tract infection testing market during the forecast period. Notable urinary tract infection testing companies such as F.
Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc.
, Danaher Corporation, ACON Laboratories, Inc., Cardinal Health, Sysmex Corporation, Abbott, Siemens Healthcare Private Limited, Laboratory Corporation of America® Holdings, Randox Lab.
